Aller au contenu principal

 Articles scientifiques

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Auteurs : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Année : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Auteurs : Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, OShaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart-Gebhart M
Année : 2023
Journal : Eur J Cancer
Volume : 178
Pages : 23-33

Do perioperative blood transfusions impact oncological outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion? Results from a large multi-institutional registry.

Auteurs : Sarkis J, Diamand R, Aoun F, Assenmacher G, Assenmacher C, Verhoest G, Holz S, Naudin M, Ploussard G, Mari A, Minervini A, Tay A, Issa R, Roumiguié M, Bajeot AS, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Hendricksen K, Einerhand S, Mertens LS, Sanchez-Salas R, Colomer A, Quackels T, Peltier A, Montorsi F, Briganti A, Pradere B, Moschini M, Roumeguère T, Albisinni S
Année : 2023
Journal : Minerva Urol Nephrol
Volume : 75
Pages : 50-58

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

Auteurs : Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A
Année : 2023
Journal : Lancet Haematol

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions.

Auteurs : Castelo-Branco L, Morgan G, Prelaj A, Scheffler M, Canhão H, van Meerbeeck JP, Awada A
Année : 2023
Journal : ESMO Open
Volume : 8
Pages : 100764

Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.

Auteurs : Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V
Année : 2023
Journal : Eur J Surg Oncol
Volume : 49
Pages : 217-224

Radiation therapy-induced left vocal cord paralysis following lung stereotactic body radiation therapy: A case report and review of the literature.

Auteurs : Pierrard J, Deheneffe S, Longton E, Henry S, Van Houtte P, Remouchamps V
Année : 2023
Journal : Cancer Radiother
Volume : 27
Pages : 69-74

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Auteurs : De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, van de Vijver KK, Amant F, Vandecasteele K, Denys HG
Année : 2023
Journal : Cancer Immunol Immunother
Volume : 72
Pages : 475-491

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.

Auteurs : Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G
Année : 2023
Journal : Ann Oncol
Volume : 34
Pages : 70-77

Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.

Auteurs : Oderda M, Albisinni S, Benamran D, Calleris G, Ciccariello M, Dematteis A, Diamand R, Descotes JL, Fiard G, Forte V, Giacobbe A, Marquis A, Marra G, Messas A, Muto G, Peltier A, Rius L, Simone G, Roumeguere T, Faletti R, Gontero P
Année : 2023
Journal : Prostate
Volume : 83
Pages : 162-168

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracy.

Auteurs : Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Albisinni S
Année : 2023
Journal : World J Urol
Volume : 41
Pages : 77-84

Role of the Prostate Imaging Quality PI-QUAL Score for Prostate Magnetic Resonance Image Quality in Pathological Upstaging After Radical Prostatectomy: A Multicentre European Study.

Auteurs : Windisch O, Benamran D, Dariane C, Favre MM, Djouhri M, Chevalier M, Guillaume B, Oderda M, Gatti M, Faletti R, Colinet V, Lefebvre Y, Bodard S, Diamand R, Fiard G
Année : 2023
Journal : Eur Urol Open Sci
Volume : 47
Pages : 94-101

Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.

Auteurs : Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Albisinni S
Année : 2023
Journal : Prostate

Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number.

Auteurs : Albisinni S, Diamand R
Année : 2023
Journal : Prostate Cancer Prostatic Dis

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.

Auteurs : Veloza L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, Bisig B, Pereira B, Bonnet C, Poullot E, Quintanilla-Martinez L, Dubois R, Llamas-Gutierrez F, Bossard C, de Wind R, Drieux F, Fontaine J, Parrens M, Sandrini J, Fataccioli V, Delfau-Larue MH, Daniel A, Lhomme F, Clément-Filliatre L, Lemonnier F, Cairoli A, Morel P, Glaisner S, Joly B, El Yamani A, Laribi K, Bachy E, Siebert R, Vallois D, Gaulard P, Tournilhac O, de Leval L
Année : 2023
Journal : Haematologica
Volume : 108
Pages : 181-195

Antibody-Drug Conjugates in Prostate Cancer: Where Are we?

Auteurs : Mjaess G, Aoun F, Rassy E, Diamand R, Albisinni S, Roumeguère T
Année : 2023
Journal : Clin Genitourin Cancer
Volume : 21
Pages : 171-174

Approaches to Fertility Preservation for Young Women With Breast Cancer.

Auteurs : Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M
Année : 2023
Journal : Clin Breast Cancer
Volume : 23
Pages : 241-248

Lymphatic Alterations Under Tattoos: Preliminary Reports of One Observational Study.

Auteurs : Bourgeois P, Roman MM, Schweicher J, Lavoisier P, Maquet P, Karler C, Lizewski M, Fouarge A, Cuylits N, Del Marmol V, Leduc O
Année : 2023
Journal : Clin Cosmet Investig Dermatol
Volume : 16
Pages : 257-265

Reply to S. Di Cosimo et al.

Auteurs : Agostinetto E, Venet D, Ignatiadis M, Kalashnikova E
Année : 2023
Journal : JCO Precis Oncol
Volume : 7
Pages : e2200644

Arterial Doppler Imaging, ABI, and Plethysmography.

Auteurs : Montemayor E, Ben Aziz M
Année : 2023
Journal : StatPearls